Snap-8 is the trade name of acetyl octapeptide-3, a synthetic chain of eight amino acids sold as an anti-wrinkle ingredient for skin creams and serums. It is marketed by the Spanish ingredient maker Lipotec and is a longer version of Argireline (acetyl hexapeptide-8), the best-known “Botox-like” cosmetic peptide (Errante et al., Front Chem 2020; Badilli and Inal, Polymers 2025). Both peptides are modeled on part of SNAP-25, a nerve-cell protein involved in releasing acetylcholine at the junction between nerve and muscle. Botulinum toxin type A works by cutting SNAP-25 (Poras et al., Appl Environ Microbiol 2009).
The idea is that a cream could soften expression lines by damping the nerve signal to facial muscles, without an injection. The evidence for this is thin. No published controlled trial has tested Snap-8 on its own in people. The only human studies used it as one ingredient among several in microneedle skin patches, and the headline wrinkle figures come from the manufacturer. Injected Snap-8 has never been studied, and it is not an approved drug.
This page summarizes what the laboratory studies, the small human studies and regulators report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Class | Synthetic acetylated octapeptide; “neurotransmitter-inhibiting” cosmetic peptide |
| Other names | Acetyl octapeptide-3 (cosmetic INCI name); acetyl glutamyl heptapeptide-3; CAS 868844-74-0 |
| Chemistry (PubChem) | C₄₁H₇₀N₁₆O₁₆S, 1075.2 g/mol |
| Relation to Argireline | Argireline’s six amino acids plus two more (alanine and aspartic acid) at one end |
| Proposed mechanism | Mimics a piece of SNAP-25 and competes with it during assembly of the SNARE complex that releases neurotransmitters |
| Studied use in people | Topical, inside dissolving microneedle patches (0.03% in one study), always combined with other actives |
| Human trials | No trial of Snap-8 alone; none of injected Snap-8 |
| Half-life | No published pharmacokinetic data |
| Regulatory status | Listed EU cosmetic ingredient with no restrictions; not an FDA-approved drug |
| WADA status | Not named on the 2026 list; the S0 catch-all for unapproved substances is broad |
What it is
Snap-8 is a short peptide (a chain of amino acids) with an acetyl group capping one end and an amide group capping the other. PubChem lists acetyl octapeptide-3 with the formula C₄₁H₇₀N₁₆O₁₆S and a molecular weight of 1075.2 g/mol, with synonyms including SNAP-8, acetyl glutamyl heptapeptide-3 and CAS number 868844-74-0 (PubChem CID 76283482). A second PubChem record filed under the name SNAP-8 shows a slightly different structure and a weight of 1073.2 g/mol (PubChem CID 71587832), and that figure is repeated in some reviews.
Its first six amino acids are the same as Argireline’s. Snap-8 adds an alanine and an aspartic acid to the end of that chain (Badilli and Inal, Polymers 2025; Shin et al., Ann Dermatol 2024). A 2020 review described it as one of the newer neurotransmitter-inhibiting peptides from Lipotec, noting that it is sold under more than one cosmetic name (acetyl octapeptide-1 or -3, and acetyl glutamyl heptapeptide-3) (Errante et al., Front Chem 2020).
| Feature | Argireline | Snap-8 |
|---|---|---|
| Cosmetic name | Acetyl hexapeptide-8 (formerly acetyl hexapeptide-3) | Acetyl octapeptide-3 |
| Length | 6 amino acids | 8 amino acids |
| Molecular weight (PubChem) | 887.0 g/mol | 1075.2 g/mol |
| Peer-reviewed lab data on mechanism | Yes, from the developers in 2002 | Manufacturer data cited in reviews |
| Placebo-controlled trials of the peptide alone | Small trials | None published |
| US CIR safety review | Safe at up to 0.005% in cosmetics | Not among the peptides the CIR panel reviewed |
Sources for the table: PubChem CID 71587772, PubChem CID 76283482, Blanes-Mira et al., Int J Cosmet Sci 2002, Bjerke et al., Curr Res Toxicol 2026.
The library also covers GHK-Cu and AHK-Cu, copper peptides used in skin care that work through a different (carrier and signaling) mechanism.
The SNARE mechanism
When a nerve tells a muscle to contract, small sacs (vesicles) inside the nerve ending release the messenger acetylcholine. To do this, each vesicle has to dock with and fuse into the cell membrane. SNAP-25 is one of the proteins that drive this step by forming the “SNARE complex” (Bjerke et al., Curr Res Toxicol 2026). Botulinum toxin type A blocks acetylcholine release by cutting SNAP-25 (Poras et al., Appl Environ Microbiol 2009).
Peptides like Argireline and Snap-8 copy a short stretch of SNAP-25. The theory is that they compete with the real protein and make the SNARE complex form less well, so less messenger is released and the muscle contracts less. In laboratory tests, the Argireline developers found that their peptide interfered with SNARE complex formation and inhibited neurotransmitter release with a potency similar to botulinum toxin A, but with much lower maximum effect (Blanes-Mira et al., Int J Cosmet Sci 2002).
For Snap-8 itself, the mechanism data are the manufacturer’s. As summarized in a 2020 review, Lipotec reports that Snap-8 at 1.5 mM reduced glutamate release (a measure of neurotransmitter release in lab assays) by 43%. In a combination test, Snap-8 alone gave 38% inhibition, the pentapeptide Leuphasyl alone 7%, and the two together (0.75 mM each) 47% (Errante et al., Front Chem 2020). These figures come from the company’s materials, not from a peer-reviewed study.
How it behaves in the body
We found no published pharmacokinetic studies of Snap-8 by any route: no half-life, absorption or breakdown data in people or animals. Any half-life figure quoted for it is not supported by published data.
The key question for a topical “Botox-like” peptide is whether it can reach the nerve endings in facial muscle at all. We found no published skin-penetration study of Snap-8. The closest data are for Argireline:
| Measure (Argireline, 10% cream, 24 h) | Human skin | Hairless guinea pig skin |
|---|---|---|
| Found in the stratum corneum (outer dead layer) | 0.22% of applied dose | 0.54% of applied dose |
| Found in the living epidermis | 0.01% | 0.01% |
| Found in the dermis or beneath the skin | None detected | None detected |
These results come from an FDA laboratory study using skin in diffusion cells; most of the peptide was simply washed off the surface (Kraeling et al., Cutan Ocul Toxicol 2015). Another lab group described Argireline’s skin permeation as poor because of its large size and its electrically charged, water-loving structure (Lim et al., Sci Rep 2018). Snap-8 is larger still (1075.2 vs 887.0 g/mol), but its penetration has not been measured.
Both published human studies of Snap-8 delivered it with dissolving microneedle patches, which create tiny channels through the outer skin layer to improve delivery (Shin et al., Ann Dermatol 2024).
Regulatory status
- European Union. Acetyl octapeptide-3 is listed in the EU cosmetic ingredient database (CosIng) with the functions “humectant” and “skin conditioning,” and with no restrictions or maximum concentration recorded (European Commission CosIng).
- United States. Cosmetic ingredients, apart from color additives, do not need FDA approval before sale. FDA notes that a product claimed to affect the structure or function of the body is legally a drug, even if it is marketed as a cosmetic, and that “cosmeceutical” has no meaning under the law (FDA). No drug containing Snap-8 has been approved.
- Safety review. The US Cosmetic Ingredient Review (CIR) expert panel concluded that Argireline (acetyl hexapeptide-8) is safe in cosmetics at concentrations up to 0.005%. Acetyl octapeptide-3 is not among the peptides listed as reviewed by the panel (Bjerke et al., Curr Res Toxicol 2026).
- Sport. Snap-8 is not named on the WADA Prohibited List. Section S0 bans any pharmacological substance not covered elsewhere on the list that has no current approval by any government health authority for human therapeutic use (WADA 2026 Prohibited List).
What the research shows
Reviews of cosmetic peptides note that most of the supporting evidence comes from laboratory (in vitro and ex vivo) work rather than randomized clinical trials, and that the strength of that evidence varies widely between peptides (Shomorony and Denton, Facial Plast Surg 2026; van Walraven et al., Peptides 2025). Snap-8 fits this pattern.
Human studies that included Snap-8
Two published human studies used Snap-8, both in hyaluronic acid microneedle patches containing other active ingredients:
| Study | Design and n | Product | Duration | Reported results |
|---|---|---|---|---|
| Shin et al., Ann Dermatol 2024 | Split-face (active patch under one eye, plain hyaluronic acid patch under the other); 24 enrolled, 21 completed | 0.03% Snap-8 + 5% vitamin C derivative + 4% cyclic lysophosphatidic acid | 28 days | Wrinkle roughness (Rz) fell more than with placebo patch at days 14 and 28 (p under 0.05); no adverse effects |
| Avcil et al., J Cosmet Dermatol 2020 | Single-center study; no placebo group described in the abstract | Snap-8 + arginine/lysine polypeptide + palmitoyl tripeptide-5 + adenosine + seaweed extracts | 12 weeks | Fine lines −25.8%, hydration +15.4%, dermal density +14.2%, thickness +12.9%; no skin reactions |
Neither study can show what Snap-8 itself does. Each product contained several active ingredients, and the comparison in the stronger study was against a patch without any of them. Both studies had industry authors, including staff of Raphas, a Korean microneedle patch company. The Shin study’s authors attributed the early wrinkle change to Snap-8 and the later benefits to the other ingredients, but the design could not separate them.
Manufacturer claims
As cited in a 2020 review, the manufacturer’s website reports an average wrinkle reduction of 35% and a maximum of 62% with Snap-8 (Errante et al., Front Chem 2020). We found no peer-reviewed publication of the study behind these figures (its size, design, comparison group and concentration), so the claims cannot be independently checked.
Evidence from the parent peptide, Argireline
Argireline has a somewhat larger evidence base. It cannot be assumed to apply to Snap-8, but it shows what this peptide class has achieved in trials:
| Study | Design and n | Result |
|---|---|---|
| Blanes-Mira et al., Int J Cosmet Sci 2002 | Developer study, healthy women, 10% Argireline cream | Wrinkle depth reduced by up to 30% after 30 days |
| Wang et al., Am J Clin Dermatol 2013 | Randomized, placebo-controlled; n = 60 (3:1 Argireline to placebo); eye wrinkles, twice daily | Global “anti-wrinkle efficacy” 48.9% vs 0% with placebo at 4 weeks; skin-replica roughness fell only with Argireline (p under 0.01) |
| Lungu et al., Eur J Neurol 2013 | Randomized, double-blind, placebo-controlled pilot; n = 24 with blepharospasm (eyelid spasm) on botulinum toxin | Non-significant trend to longer toxin effect: 3.7 vs 3.0 months; no significant adverse events |
The NIH blepharospasm pilot is notable because it measured a muscle outcome rather than the look of the skin, and it found only a non-significant trend.
Side effects and risks
Topical use
In the two microneedle patch studies, no adverse effects or skin reactions were reported (Shin et al., Ann Dermatol 2024; Avcil et al., J Cosmet Dermatol 2020). These studies were small and short. We found no published toxicology studies of Snap-8 itself, and it has not been through a CIR safety review.
For Argireline, the developers reported no oral toxicity or primary skin irritation at high doses (Blanes-Mira et al., Int J Cosmet Sci 2002). In cell culture, Argireline reduced cell growth in a dose-dependent way, but only at concentrations 18 to 10,000 times higher than those of the cancer drug doxorubicin used as a comparison (Grosicki et al., Acta Biochim Pol 2014).
Injection
Injection is outside any studied use of Snap-8. There are no human or animal data on injected Snap-8: no dose-finding, no safety data and no information on whether it has any effect on muscle when injected.
A related case shows one concrete risk. A 45-year-old woman developed red nodules and abscesses at the injection sites on her forehead and temples one week after Argireline injections. Cultures grew Mycobacterium abscessus, and she needed two antibiotics (clarithromycin and moxifloxacin) for 5 months (Chen et al., World J Clin Cases 2021). The authors noted that this infection is easily mistaken for a common bacterial infection and that standardized cosmetic procedures can prevent it.
Product quality
Argireline contains a methionine, an amino acid that oxidizes easily. A lab analysis of commercial creams and serums found both intact and oxidized Argireline, and the authors noted that other ingredients can affect the peptide’s stability (Kluczyk et al., Chem Biodivers 2021). Snap-8 contains the same methionine. We found no published independent testing of the content or purity of Snap-8 products, topical or injectable.
Key takeaways
- A longer version of Argireline. Snap-8 (acetyl octapeptide-3) adds two amino acids to the six of Argireline and is designed to mimic part of SNAP-25, the protein botulinum toxin targets.
- Mechanism data are the manufacturer’s. Figures such as 43% inhibition of glutamate release in lab assays come from company materials cited in reviews, not from peer-reviewed studies.
- No trial of Snap-8 alone. The two human studies used multi-ingredient microneedle patches, so they cannot show what Snap-8 contributes. The often-quoted 35% average wrinkle reduction comes from the manufacturer, not a peer-reviewed study.
- Getting into the skin is the main hurdle. No penetration study exists for Snap-8; for the smaller Argireline, an FDA lab found only about 0.01% of the dose in the living epidermis and none deeper.
- A cosmetic ingredient, not a drug. It is listed for cosmetic use in the EU, needs no FDA approval as a cosmetic ingredient, and is not an approved medicine. Injected Snap-8 has no safety or efficacy data.
Sources
- Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:572923. PubMed; PMC.
- Badilli U, Inal O. Current approaches in cosmeceuticals: peptides, biotics and marine biopolymers. Polymers (Basel). 2025;17(6):798. PubMed.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 76283482, Acetyl octapeptide-3. PubChem.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 71587832, SNAP-8. PubChem.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 71587772, Acetyl hexapeptide-8 (Argireline). PubChem.
- Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–310. PubMed.
- Bjerke DL, Li J, Gao Y, et al. A framework for the safety evaluation of peptides in cosmetics. Curr Res Toxicol. 2026;10:100291. PubMed; PMC.
- Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46–52. PubMed.
- Lim SH, Sun Y, Thiruvallur Madanagopal T, et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Sci Rep. 2018;8(1):1596. PubMed.
- European Commission. CosIng cosmetic ingredient database: Acetyl Octapeptide-3 (substance ID 82188). European Commission.
- US Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Content current as of September 11, 2024. FDA.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 Prohibited List.
- Shomorony A, Denton AJ. Peptides in facial plastic surgery: emerging applications in aesthetics and rejuvenation. Facial Plast Surg. 2026;42(3):417–419. PubMed.
- van Walraven N, FitzGerald RJ, Danneel HJ, Amigo-Benavent M. Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence. Peptides. 2025;193:171440. PubMed.
- Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical safety and efficacy evaluation of a dissolving microneedle patch having dual anti-wrinkle effects with safe and long-term activities. Ann Dermatol. 2024;36(4):215–224. PubMed; PMC.
- Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study. J Cosmet Dermatol. 2020;19(2):328–337. PubMed.
- Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147–153. PubMed.
- Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013;20(3):515–518. PubMed.
- Grosicki M, Latacz G, Szopa A, Cukier A, Kieć-Kononowicz K. The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochim Pol. 2014;61(1):29–32. PubMed.
- Chen CF, Liu J, Wang SS, Yao YF, Yu B, Hu XP. Mycobacterium abscessus infection after facial injection of argireline: a case report. World J Clin Cases. 2021;9(8):1996–2000. PubMed.
- Kluczyk A, Ludwiczak J, Modzel M, et al. Argireline: needle-free Botox as analytical challenge. Chem Biodivers. 2021;18(3):e2000992. PubMed.
- Poras H, Ouimet T, Orng SV, et al. Detection and quantification of botulinum neurotoxin type A by a novel rapid in vitro fluorimetric assay. Appl Environ Microbiol. 2009;75(13):4382–4390. PubMed.